Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line): appeal

Selected, reliable information for health and social care in one place

• NICE on Twitter

  @NICEcomms

  Follow @NICEcomms on Twitter

• Subscribe to NICE

  • If you are an NHS or public health professional you are eligible to receive NICE guidance by email and post where available.
  • Subscribe to the NICE RSS Feed
  • Stay informed when new content in your area of interest is added to the NICE website
  • Subscribe to NICE news, our free monthly e-newsletter

• Share NICE

  Top Guidance Trends